The BioCentury 100 reached a record high in March, before falling 6% on fears of a correction (but still up 19% on 4Q14). $37 billion in funding was raised, excluding partnership monies. Equity issuances by public biotechs came in at $14 billion, up 59% from 1Q14. Compared with 1Q14, follow-on offerings and public firm debt more than doubled, the latter increase driven by a Valeant Pharmaceuticals' $10.1-billion note deal in its Salix Pharmaceuticals' acquisition. Private biotechs raised $3 billion, led by Moderna Therapeutics' $450-million round.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yang, W. Biotech continues to soar in 1Q15. Nat Biotechnol 33, 442 (2015). https://doi.org/10.1038/nbt.3229
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3229
